



Alu and LINE-1 Methylation and Lung Function in the Normative Aging Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001231
Article Type:	Research
Date Submitted by the Author:	26-Apr-2012
Complete List of Authors:	Lange, Nancy; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine Sordillo, Joanne; Channing Laboratory, Brigham and Women's Hospital, Tarantini, Letizia; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Bollati, Valentina; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Sparrow, David; VA Boston Healthcare System and Boston University School of Medicine, Medicine Vokonas, Pantel; VA Boston Healthcare System and Boston University School of Medicine, Medicine Zanobetti, Antonella; Harvard School of Public Health, Environmental and Occupational Health Schwartz, Joel; Harvard School of Public Health, Environmental Health; Harvard School of Public Health, Environmental and Occupational Health Baccarelli, Andrea; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Litonjua, Augusto; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine DeMeo, Dawn; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Epidemiology, Genetics and genomics
Keywords:	EPIDEMIOLOGY, GENETICS, Thoracic medicine < INTERNAL MEDICINE, Emphysema < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

***Alu* and LINE-1 Methylation and Lung Function in the Normative Aging Study**

Short Title: Global Methylation and Lung Function

Nancy E. Lange MD MPH,¹⁻³ Joanne Sordillo ScD^{1,3} Letizia Tarantini BS,⁴ Valentina Bollati PhD,⁴ David Sparrow DSc,⁵ Pantel Vokonas MD,⁵ Antonella Zanobetti PhD,⁶ Joel Schwartz PhD,⁶ Andrea Baccarelli MD PhD,^{4,6} Augusto A. Litonjua MD MPH¹⁻³, Dawn L. DeMeo MD MPH¹⁻³

¹Channing Laboratory, ²Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; ³Harvard Medical School, Boston, MA, USA; ⁴Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health, Università degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy; ⁵Veterans Administration Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, MA, USA; ⁶Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.

Corresponding author:

Nancy E. Lange, MD, MPH
Channing Laboratory
Brigham and Women's Hospital
181 Longwood Avenue, room 454
Boston, MA 02115, USA
Phone: 617-525-0874
Fax: 617-525-0958
Email: renal@channing.harvard.edu

Key Words: epigenetics, global methylation, FEV₁, FVC, exposure

Word count:

Abstract: 217
Manuscript: 2057

ABSTRACT

Objectives: To investigate the association between methylation of transposable elements *Alu* and LINE-1 and lung function.

Design: Cohort study

Setting: Outpatient Veterans Administration facilities in greater Boston, MA, USA.

Participants: Subjects from the Veterans Administration Normative Aging Study, a longitudinal study of aging, evaluated between 1999 and 2007.

Primary and secondary outcome measures: Primary predictor was methylation, assessed using PCR-pyrosequencing after bisulfite treatment. Primary outcome was lung function as assessed by spirometry, performed according to ATS/ERS guidelines at the same visit as the blood draws.

Results: In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking and race, *Alu* hypomethylation was associated with lower FEV₁ ($\beta=28\text{ml}$ per 1% change in *Alu* methylation, $p=.017$), FVC ($\beta=27\text{ml}$, $p=.06$) and lower FEV₁/FVC ($\beta=0.3\%$, $p=.058$). In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking, % lymphocytes, race and baseline lung function, LINE-1 hypomethylation was associated with more rapid decline of FEV₁ ($\beta=6.9\text{ml/yr}$ per 1% change in LINE-1 methylation, $p=.005$) and of FVC ($\beta=9.6\text{ml/yr}$, $p=.002$).

Conclusions: In multiple regression analysis, *Alu* hypomethylation was associated with lower lung function, and LINE-1 hypomethylation was associated with more rapid lung function decline. Future studies should aim to replicate these findings and determine if *Alu* or LINE-1 hypomethylation may be due to specific and modifiable environmental exposures.

1
2
3 **Article Summary:**
4

5 **Article Focus:**
6

7 Association between methylation, an epigenetic marker, and lung function
8

9 **Key Message(s):**
10

11 Hypomethylation of transposable elements is associated with lower lung function and more rapid
12 lung function decline in a cohort of elderly North American men.
13

14 **Strengths and Limitations:**
15

16 First study to evaluate methylation of transposable elements in relation to lung function.
17

18 Difficult to interpret implications of methylation patterns in transposable elements.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Lung function has both environmental and genetic determinants.¹⁻⁴ Epigenetic changes, which may influence gene expression patterns without changing DNA sequence, may mediate the effects of environmental exposures on disease outcomes. DNA methylation, one type of epigenetic change, is the reversible addition of a methyl group to cytosine nucleotides. Methylation changes may or may not persist over time in the human genome, as epigenetic marks are highly plastic.

A large portion of methylation sites within the genome are found in repeat sequences and transposable elements, such as *Alu* and LINE-1 (long interspersed nuclear element) which are among the most common and best characterized repetitive elements.⁵⁻⁷ *Alu* is the most abundant of the SINEs (short-interspersed nuclear elements) with over one million copies per genome.⁸ *Alu* elements compose approximately 11% of the mass of human genome and contain 30% of its methylation sites.^{6,9} LINE-1 elements are present at over half a million copies.^{8,10} Methylation of repetitive elements such as *Alu* and LINE-1 has been shown to correlate with total genomic methylation content.^{10,11} Hypomethylation in transposable elements is associated with higher genomic instability and alterations or deregulation of gene expression.^{12,13}

Prior studies have found associations between methylation of *Alu* or LINE-1 elements and various diseases including multiple cancers,⁶ cardiovascular disease¹⁴⁻¹⁶ and neurologic disease¹⁷ as well as with markers of inflammation¹⁸ and the inflammatory response.¹⁹ Studies on gene-specific methylation and non-neoplastic lung disease have found associations between GATA4, CDKN2A (p16) and lung function and an interaction with wood smoke exposure.²⁰ To our knowledge no prior study has investigated associations between methylation of transposable elements and non-neoplastic lung disease. Moreover, case-control studies such as are common in genomic studies are more problematic for epigenetic marks since sampling cases after disease onset makes it impossible to determine whether epigenetic changes preceded the disease. Hence cohort studies or nested case-control studies within cohorts are particularly valuable. Our aim was to examine whether methylation of the repetitive elements *Alu* and LINE-1 was associated with measures of lung function, COPD status, and longitudinal change in lung function in a

1
2
3 cohort of men, the Normative Aging Study. Preliminary results from these analyses were previously
4 reported in abstract form.²¹
5
6
7
8
9

10 METHODS

11 Population:

12
13
14
15
16 Study participants were from the Veterans Administration Normative Aging Study, an ongoing
17 longitudinal study of aging established in 1963.²² This is a cohort of 2,280 healthy male volunteers from
18 the greater Boston, MA, area who were 21–80 years of age at entry and who enrolled after an initial
19 health screening determined that they were free of known chronic medical conditions. Participants were
20 reevaluated every 3–5 years using detailed on-site physical examinations and questionnaires. The study
21 was approved by the Institutional Review Boards of all participating institutions. All participants gave
22 written informed consent.
23
24
25
26
27
28
29

30 For this study, individuals evaluated at least once between January 1999 and June 2007 with a
31 blood sample drawn and concomitant spirometry were included. During the study period, this included
32 663 total subjects, 194 of whom reported for examination two times, for a total of 857 samples collected.
33
34
35
36
37

38 Measures:

39
40 Spirometry was performed according to ATS/ERS guidelines.²³ All spirometric values are pre-
41 bronchodilator. Percent predicted values for FEV₁ and FVC were calculated using equations by Crapo *et*
42 *al.*²⁴ COPD was defined as GOLD stage II or higher (FEV₁/FVC<70% and FEV₁<80% predicted).²⁵
43
44 Techniques for assessing DNA methylation were previously described in detail.^{26 27} Briefly, we performed
45 DNA methylation assessment of *Alu* and LINE-1 repetitive elements on bisulfite-treated blood leukocyte
46 DNA using highly quantitative polymerase chain reaction (PCR)–pyrosequencing technology. The degree
47 of methylation was expressed as the percentage of methylated cytosines over the sum of methylated and
48 unmethylated cytosines. Each marker was tested in triplicate, and their average was used in the statistical
49 analysis.
50
51
52
53
54
55
56
57
58
59
60

Statistical Analysis

Analyses for cross-sectional associations were performed using repeated measures with adjustment for the correlation between measurements in a given individual using mixed effects models (PROC MIXED) for continuous outcomes (FEV₁, FVC, FEV₁/FVC) and generalized estimating equations (PROC GENMOD) for binary outcomes (COPD). Covariates in multivariable models were chosen for their clinical relevance and strong bivariate associations ($p \leq 0.05$) with lung function or change in effect estimate criterion of >10% after addition to the model and included age, height, race, pack-years of cigarette smoking, smoking status (dichotomized as current vs. ex and never smokers) and body mass index (BMI). We also considered variables previously associated with methylation of repetitive elements²⁸ such as folate intake, alcohol intake, total white blood cell count and both percent neutrophils and percent lymphocytes. With the exception of percent lymphocytes, which was included in models with LINE-1 only, these covariates were not included in final models because they were not associated with *Alu* or LINE-1 methylation and did not meet the change in estimate criteria. Because Figure 2 depicts bivariate relationships, percent predicted values were used for both FEV₁ and FVC to show an adjusted value; actual values for FEV₁ and FVC were utilized in multivariable models. To examine associations between methylation of *Alu* and LINE-1 and change in lung function over time, a rate was calculated using the change in lung function between the two time points divided by the amount of time elapsed between the two measurements in years. This value was utilized as an outcome and analyzed using multivariate linear regression models. A total of 301 subjects had a second lung function data point subsequent to the initial methylation value. SAS version 9.1 (SAS Institute, Cary, NC) was used for all analyses.

RESULTS

Baseline characteristics of the 663 individuals included in this study are shown in **Table 1**. All subjects were male and the majority (640, 97%) of white race. Few subjects were current smokers and 197 (30%) were never smokers. There was wide variation in lung function values. Of the 107 individuals

1
2
3 with COPD, 77 (72%) were GOLD stage II, 26 were stage III and 4 were stage IV; overall 20 (20%) of the
4
5 individuals with COPD were current smokers.
6
7

8 The distribution of percentage methylation of both *Alu* and LINE-1 elements among the
9
10 population is shown in **Figure 1**.
11

12
13 Bivariate relationships between *Alu* and LINE-1 with outcomes and covariates considered for
14
15 inclusion in the multivariable model are shown in **Table 2**. *Alu* methylation was associated or showed a
16
17 trend towards association positively with FEV₁, BMI and FEV₁/FVC and negatively with age and COPD
18
19 status. LINE-1 was positively associated with current smoking and negatively with percent lymphocytes.
20
21 Neither *Alu* nor LINE-1 was associated with FVC, pack-years of smoking or ever smoking status. Folate
22
23 intake, alcohol intake, total white blood cell count and percent neutrophils were not significantly
24
25 associated with *Alu* or LINE-1 in bivariate analyses. There was no significant relationship between
26
27 methylation of *Alu* and LINE-1 to each other (p=.23).
28

29
30 In multivariate models that included age, height, race, pack-years of smoking, smoking status,
31
32 and BMI, *Alu* methylation was positively associated with FEV₁, FEV₁/FVC and showed a trend towards
33
34 association with FVC. When analyzed excluding current smokers, there was a negative association
35
36 between *Alu* and COPD (higher *Alu* with lower odds of COPD) that was statistically significant (OR 0.80
37
38 [0.64, 0.99] p=.046). There were no significant associations between LINE-1 and any of the outcomes.
39
40 (**Table 3**). **Figure 2** depicts the bivariate associations of *Alu* methylation with FEV₁ % predicted, FVC %
41
42 predicted and FEV₁/FVC.
43

44
45 We also analyzed whether methylation of *Alu* and LINE-1 were associated with rate of change in
46
47 lung function in a subset of participants who had two consecutive lung function measures (N=301). The
48
49 mean number of years elapsed between measurements was 4.03 (SD 1.23). Models were adjusted for
50
51 baseline FEV₁, FVC or FEV₁/FVC (respectively for the given outcome) as well as age, pack-years of
52
53 smoking, BMI, height, race, percent lymphocytes and smoking status. LINE-1 but not *Alu* was associated
54
55 negatively with rate of change in FEV₁ and FVC (p<.005). Neither measure was associated with rate of
56
57
58
59
60

1
2
3 change of FEV₁/FVC. (Table 4) Including both *Alu* and LINE-1 in the models did not change the results
4
5 (data not shown).
6
7
8
9

10 11 DISCUSSION

12
13 We examined associations between methylation levels of the repetitive elements *Alu* and LINE-1
14 in a cohort of elderly men in relation to lung function and COPD status. In cross-sectional analyses, we
15 found that *Alu* hypomethylation was associated with lower FEV₁ with a trend towards association with
16 lower FVC and FEV₁/FVC. LINE-1 hypomethylation was associated with more rapid lung function decline
17 (FEV₁ and FVC).
18
19
20
21
22

23
24 Prior studies have found associations between methylation of repetitive transposable elements
25 such as *Alu* and LINE-1 and several diseases including multiple cancers,⁶ cardiovascular disease¹⁴⁻¹⁶ and
26 neurologic disease¹⁷ as well as with markers of inflammation.¹⁸ To our knowledge this is the first study to
27 examine associations between methylation of *Alu* and LINE-1 transposable elements and measures of
28 lung function.
29
30
31
32

33
34 Previous work has shown that in normal subjects, *Alu* hypomethylation is associated with
35 increased age^{7,29}, greater alcohol use and gender (lower in males).²⁸ In this same cohort (NAS),
36 hypomethylation has been associated with higher incidence of cancer in general and lung cancer
37 specifically (LINE-1), as well as higher mortality from cancer (*Alu* and LINE-1).³⁰ A variety of
38 environmental exposures such as lead³¹ traffic particles²⁷ organic pollutants,³² metals, air pollutants and
39 endocrine disrupting agents³³ may all affect global methylation levels, specifically some that may relate to
40 lung function such as various air pollutants.
41
42
43
44
45
46

47
48 Hypomethylation of transposable elements may or may not be causally linked to lower lung
49 function and faster rates of lung function decline. Lower methylation of *Alu* and LINE-1 may increase their
50 activity as retrotransposable sequences, leading to greater genomic instability and more mutations.¹²
51 Furthermore, oxidative damage caused by environmental exposures may cause hypomethylation.³⁴ This
52 may lead to alteration of gene expression through a variety of mechanisms including disrupting
53 transcription factor binding sites or reading frames, altering regulatory sequences, altering methylation
54
55
56
57
58
59
60

1
2
3 patterns of gene promoters, or introducing new transcription factor binding sites.³⁵⁻³⁷ *Alu* elements
4 specifically are preferentially found in gene-rich regions.³⁸ Black carbon and increased PM_{2.5} exposure²⁷
5 as well as PM₁₀ exposure³³ have been found to be inversely associated with LINE-1 and both *Alu* and
6 LINE-1 methylation, respectively which may impact lung function or lung function decline.³⁹ LINE-1
7 hypomethylation may also increase transcription of genes that have LINE-1 in regulatory regions. It is
8 possible that other specific environmental or dietary exposures previously not known to be associated
9 with lung function may be mediated through epigenetic changes such as *Alu* or LINE-1 hypomethylation.
10 Alternatively, this may be a marker of a specific exposure but not causally linked to lower lung function.
11 Lastly, because *Alu* methylation decreases with increasing age, as does lung function, our findings may
12 represent some other measure of 'aging' or exposures resulting in similar processes beyond just
13 chronological age.⁷ As our understanding of epigenetic processes and the exposures that affect these
14 processes increases, the implications of our findings will become clearer.

15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

These data must be interpreted in the context of the study design. Our study was limited to elderly men the majority of whom were white, and our findings may or may not be generalizable to other populations. It is difficult to know how to interpret methylation of retrotransposons, as opposed to gene-specific methylation, in relation to specific outcomes such as lung function and lung function decline. Future studies should include gene-specific methylation analyses to elucidate mechanisms by which methylation changes may relate to these outcomes. We did not control for a variety of environmental exposures that may be associated with both lung function and methylation, however, alteration in methylation patterns may be the pathway through which these changes are mediated and thus including these exposures in multivariate models would be overadjusting. Methylation levels vary in different tissue types and it is possible that assessments of methylation in white blood cells may not reflect alterations seen in lung tissue. However, systemic processes involving white blood cells, such as inflammation, may play a role in the pathophysiology of lung function decline⁴⁰ and may nonetheless be markers of specific exposures (such as cigarette smoking) that exert a systemic effect.

In summary, we found that relative hypomethylation of *Alu* was associated with lower lung function measures, and that LINE-1 hypomethylation was associated with more rapid lung function decline. Future studies on both gene-specific methylation as well as exposures related to methylation of

1
2
3 retrotransposons will improve our understanding of the relationship between epigenetic changes and lung
4
5 function, potentially informing new diagnostic and therapeutic approaches to lung function decline.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

Table 1: Baseline characteristics of 663 individuals from the Normative Aging Study

	Mean (SD) or N (%)	Range
Age	72.7 (6.7)	(55.3-100.9)
BMI	28.5 (4.2)	(19.4-52.3)
Pack-years*	30.6 (24.8)	(0.1-145.5)
Current smokers	43 (7%)	
Ever smokers	466 (70%)	
FEV₁	2.70 (.64)	(.85-4.69)
FEV₁%pred	81 (17)	(28-125)
FVC	3.56 (0.72)	(1.63-6.32)
FVC%pred	82 (14)	(43-124)
FEV₁/FVC	75 (8)	(36-94)
COPD	107 (16%)	
Alu	26.4 (1.1)	(22.8-32.4)
LINE-1	76.8 (1.8)	(70.1-84.6)

*pack-years in current or ex-smokers only

Table 2: Bivariate associations between *Alu*, LINE-1 and other covariates

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
Age	-0.3	0.07	-0.2	0.1
BMI	0.106	0.059	0.054	0.17
Current smoking	0.35	0.14	0.697	0.0002
% Lymphocytes	0.08	0.73	-0.31	0.04
FEV₁	0.024	0.06	-0.006	0.53
FEV₁/FVC	0.31	0.046	-0.05	0.67
COPD	OR .87 [.73, 1.03]	0.1	1.02 [.92, 1.13]	0.76

Table 3: Multivariate models for lung function and both *Alu* and LINE-1 methylation*

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
FEV₁	0.028	0.017	-0.015	0.08
FVC	0.027	0.06	-0.017	0.11
FEV₁/FVC	0.3	0.057	-0.092	0.44
COPD	0.85 [0.71, 1.03]	0.09	1.01 [.89, 1.15]	0.83

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status. Models with LINE-1 also include % lymphocytes.

Table 4: Multivariate models for rate of change in lung function (in liters/yr) and both *Alu* and LINE-1 methylation*

	FEV ₁ rate		FVC rate		ratio rate	
	β	p val	β	p val	β	p val
<i>Alu</i>	-0.0028	0.49	-0.00098	0.84	-0.00079	0.17
LINE-1	-0.0069	0.005	-0.0096	0.0021	0.00005	0.89

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status, and baseline FEV₁, FVC or FEV₁/FVC respectively depending on outcome. Models with LINE-1 also adjusted for % lymphocytes.

For peer review only

1
2
3 **Figure Legends**
4

5 **Figure 1:** Distribution (median, interquartile range) of percentage *Alu* and LINE-1 methylation
6

7 **Figure 2: *Alu* Methylation and Lung Function**

8 Bivariate associations between *Alu* and FEV₁%predicted, FVC%predicted and FEV₁/FVC
9

10 * For FEV₁/FVC y axis is percent, not percent predicted
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **ACKNOWLEDGMENTS:** We would like to thank all of the participants of the Normative Aging Study.
4

5 **COMPETING INTERESTS:** None of the authors have any competing interests to report.
6


7 **FUNDING:** Funded by NIH grants AG027214, ES015172, ES014663, HL007427, HL089438, ES015172-
8 01 and ES000002, and VA Research and Development Service. Dr. DeMeo is supported by a Doris Duke
9 Clinical Scientist Development Award. The Cooperative Studies Program/Epidemiology Research and
10 Information Center of the U.S. Department of Veterans Affairs supported the VA Normative Aging Study,
11 which is a component of the Massachusetts Veterans Epidemiology Research and Information Center,
12 Boston, MA.
13

14 **AUTHOR CONTRIBUTIONS:** N.E.L. designed the study, performed the data analysis, and prepared the
15 manuscript. J.S. contributed to the data analysis and provided critical revision of the manuscript. L.T.
16 contributed to data collection and provided critical revision of the manuscript. V.B. contributed to data
17 collection and provided critical revision of the manuscript. D.S. and P.V. were involved in conception of
18 the study and critical revision of the manuscript. A.Z. contributed to data collection and provided critical
19 revision of the manuscript. J.S. contributed to study design and provided critical revision of the
20 manuscript. A.B. contributed to data collection and provided critical revision of the manuscript. A.A.L.
21 contributed to study design, assisted with the data analysis, and provided critical revision of the
22 manuscript. D.L.D. designed the study, assisted with the data analysis, and provided critical revision of
23 the manuscript.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60


References:

1. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marcianti KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet*;42(1):45-52.
2. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. *Am Rev Respir Dis* 1982;125(4):409-15.
3. McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J Gerontol* 1994;49(6):264-8.
4. Redline S, Tishler PV, Rosner B, Lewitter FI, Vandenburg M, Weiss ST, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. *Am J Epidemiol* 1989;129(4):827-36.
5. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. *Nucleic Acids Res* 1982;10(8):2709-21.
6. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. *Biochim Biophys Acta* 2007;1775(1):138-62.
7. Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. *Mech Ageing Dev* 2009;130(4):234-9.
8. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409(6822):860-921.
9. Deininger PL, Batzer MA. Alu repeats and human disease. *Mol Genet Metab* 1999;67(3):183-93.
10. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32(3):e38.
11. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33(21):6823-36.
12. Gravina S, Vijg J. Epigenetic factors in aging and longevity. *Pflugers Arch* 2010;459(2):247-58.
13. Dean W, Lucifero D, Santos F. DNA methylation in mammalian development and disease. *Birth Defects Res C Embryo Today* 2005;75(2):98-111.
14. Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology* 2010;21(6):819-28.
15. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 2003;49(8):1292-6.
16. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. *PLoS One* 2010;5(3):e9692.
17. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA methylation in repetitive elements and Alzheimer disease. *Brain Behav Immun* 2011.
18. Baccarelli A, Tarantini L, Wright RO, Bollati V, Litonjua AA, Zanobetti A, et al. Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. *Epigenetics* 2010;5(3).
19. Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. *Autoimmunity* 2010;43(1):7-16.
20. Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. *Am J Respir Crit Care Med* 2010;182(9):1098-104.

21. Lange NE, Sordillo JE, Tarantini L, Bollati V, Sparrow D, Vokonas P, et al. Global DNA Methylation and Lung Function in the Normative Aging Study [abstract]. *Am J Respir Crit Care Med* 2011;183:A5694.
22. Bell B, Rose C, Damon A. The Normative Aging Study: an interdisciplinary and longitudinal study of health and aging. *Aging and Human Development* 1972;3:5-17.
23. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. *Eur Respir J* 2005;26(2):319-38.
24. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;123(6):659-64.
25. Harris SS. Vitamin D and African Americans. *J Nutr* 2006;136(4):1126-9.
26. Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. *Cancer Res* 2007;67(3):876-80.
27. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH, et al. Rapid DNA methylation changes after exposure to traffic particles. *Am J Respir Crit Care Med* 2009;179(7):572-8.
28. Zhu ZZ, Hou L, Bollati V, Tarantini L, Marinelli B, Cantone L, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. *Int J Epidemiol* 2010.
29. Jintaridth P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. *Physiol Genomics* 2010;41:194-200.
30. Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, Litonjua AA, et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. *Cancer Causes Control* 2010;22(3):437-47.
31. Pilsner JR, Hu H, Ettinger A, Sanchez BN, Wright RO, Cantonwine D, et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 2009;117(9):1466-71.
32. Rusiecki JA, Baccarelli A, Bollati V, Tarantini L, Moore LE, Bonfeld-Jorgensen EC. Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. *Environ Health Perspect* 2008;116(11):1547-52.
33. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr* 2009;21(2):243-51.
34. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 2004;32(14):4100-8.
35. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, et al. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. *J Biol Chem* 1995;270(39):22777-82.
36. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. *Proc Natl Acad Sci U S A* 1995;92(18):8229-33.
37. Asada K, Kotake Y, Asada R, Saunders D, Broyles RH, Towner RA, et al. LINE-1 hypomethylation in a choline-deficiency-induced liver cancer in rats: dependence on feeding period. *J Biomed Biotechnol* 2006;2006(1):17142.
38. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. *Nat Rev Genet* 2002;3(5):370-9.
39. Andersen ZJ, Hvidberg M, Jensen SS, Kettel M, Loft S, Sorensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. *Am J Respir Crit Care Med* 2010;183(4):455-61.
40. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. *Chest* 2011;139(1):165-73.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43



Alu and LINE-1 Methylation and Lung Function in the Normative Aging Study

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2012-001231.R1
Article Type:	Research
Date Submitted by the Author:	01-Aug-2012
Complete List of Authors:	Lange, Nancy; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine Sordillo, Joanne; Channing Laboratory, Brigham and Women's Hospital, Tarantini, Letizia; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Bollati, Valentina; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Sparrow, David; VA Boston Healthcare System and Boston University School of Medicine, Medicine Vokonas, Pantel; VA Boston Healthcare System and Boston University School of Medicine, Medicine Zanobetti, Antonella; Harvard School of Public Health, Environmental and Occupational Health Schwartz, Joel; Harvard School of Public Health, Environmental Health; Harvard School of Public Health, Environmental and Occupational Health Baccarelli, Andrea; Universita degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health Litonjua, Augusto; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine DeMeo, Dawn; Brigham and Women's Hospital, Channing Laboratory/Division of Pulmonary and Critical Care Medicine
Primary Subject Heading:	Respiratory medicine
Secondary Subject Heading:	Epidemiology, Genetics and genomics
Keywords:	EPIDEMIOLOGY, GENETICS, Thoracic medicine < INTERNAL MEDICINE, Emphysema < THORACIC MEDICINE

SCHOLARONE™
Manuscripts

***Alu* and LINE-1 Methylation and Lung Function in the Normative Aging Study**

Short Title: Global Methylation and Lung Function

Nancy E. Lange MD MPH,¹⁻³ Joanne Sordillo ScD^{1,3} Letizia Tarantini BS,⁴ Valentina Bollati PhD,⁴ David Sparrow DSc,⁵ Pantel Vokonas MD,⁵ Antonella Zanobetti PhD,⁶ Joel Schwartz PhD,⁶ Andrea Baccarelli MD PhD,^{4,6} Augusto A. Litonjua MD MPH¹⁻³, Dawn L. DeMeo MD MPH¹⁻³

¹Channing Division of Network Medicine, ²Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; ³Harvard Medical School, Boston, MA, USA; ⁴Center of Molecular and Genetic Epidemiology, Department of Environmental and Occupational Health, Università degli Studi di Milano and IRCCS Maggiore Policlinico Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy; ⁵Veterans Administration Boston Healthcare System and Department of Medicine, Boston University School of Medicine, Boston, MA, USA; ⁶Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.

Corresponding author:

Nancy E. Lange, MD, MPH
Channing Laboratory
Brigham and Women's Hospital
181 Longwood Avenue, room 454
Boston, MA 02115, USA
Phone: 617-525-0874
Fax: 617-525-0958
Email: renal@channing.harvard.edu

Key Words: epigenetics, global methylation, FEV₁, FVC, exposure

Word count:

Abstract: 247
Manuscript: 2390

ABSTRACT

Objectives: To investigate the association between methylation of transposable elements *Alu* and LINE-1 and lung function.

Design: Cohort study

Setting: Outpatient Veterans Administration facilities in greater Boston, MA, USA.

Participants: Subjects from the Veterans Administration Normative Aging Study, a longitudinal study of aging in men, evaluated between 1999 and 2007. The majority (97%) of subjects were white.

Primary and secondary outcome measures: Primary predictor was methylation, assessed using PCR-pyrosequencing after bisulfite treatment. Primary outcome was lung function as assessed by spirometry, performed according to ATS/ERS guidelines at the same visit as the blood draws.

Results: In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking and race, *Alu* hypomethylation was associated with lower FEV₁ ($\beta=28\text{ml}$ per 1% change in *Alu* methylation, $p=.017$) and showed a trend towards association with a lower FVC ($\beta=27\text{ml}$, $p=.06$) and lower FEV₁/FVC ($\beta=0.3\%$, $p=.058$). In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking, % lymphocytes, race and baseline lung function, LINE-1 hypomethylation was associated with more rapid decline of FEV₁ ($\beta=6.9\text{ml/yr}$ per 1% change in LINE-1 methylation, $p=.005$) and of FVC ($\beta=9.6\text{ml/yr}$, $p=.002$).

Conclusions: In multiple regression analysis, *Alu* hypomethylation was associated with lower lung function, and LINE-1 hypomethylation was associated with more rapid lung function decline in a cohort of older and primarily white men from North America. Future studies should aim to replicate these findings

1
2
3 and determine if *Alu* or LINE-1 hypomethylation may be due to specific and modifiable environmental
4 exposures.
5
6
7

8
9 **Article Summary:**

10
11 **Article Focus:**

12 Association between methylation, an epigenetic marker, and lung function
13

14
15 **Key Message(s):**

16
17 Relative hypomethylation of transposable elements is associated with lower lung function and
18 more rapid lung function decline in a cohort of older North American primarily white men.
19

20
21 **Strengths and Limitations:**

22 First study to evaluate methylation of transposable elements in relation to lung function.
23

24 Difficult to interpret implications of methylation patterns in transposable elements.
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Lung function has both environmental and genetic determinants.¹⁻⁵ Epigenetic variation, which may influence gene expression patterns without changing DNA sequence, may mediate the effects of environmental exposures on disease outcomes. DNA methylation, one type of epigenetic change, is the reversible addition of a methyl group to cytosine nucleotides. Methylation changes may or may not persist over time in the human genome, as epigenetic marks are highly plastic.

A large portion of methylation sites within the genome are found in repeat sequences and transposable elements, such as *Alu* and LINE-1 (long interspersed nuclear element) which are among the most common and best characterized repetitive elements.⁶⁻⁸ *Alu* is the most abundant of the SINEs (short-interspersed nuclear elements) with over one million copies per genome.⁹ *Alu* elements compose approximately 11% of the mass of human genome and contain 30% of its methylation sites.^{7 10} LINE-1 elements are present at over half a million copies.^{9 11} Methylation of repetitive elements such as *Alu* and LINE-1 has been shown to correlate with total genomic methylation content.^{11 12} Hypomethylation in transposable elements is associated with higher genomic instability and alterations or deregulation of gene expression.^{13 14}

Prior studies have found associations between methylation of *Alu* or LINE-1 elements and various diseases including multiple cancers,⁷ cardiovascular disease¹⁵⁻¹⁷ and neurologic disease¹⁸ as well as with markers of inflammation¹⁹ and the inflammatory response.²⁰ Studies on gene-specific methylation and non-neoplastic lung disease have found associations between GATA4, CDKN2A (p16) and lung function and an interaction with wood smoke exposure,²¹ as well as multiple genes in association with COPD presence and severity.²² To our knowledge no prior study has investigated associations between methylation of transposable elements and non-neoplastic lung disease. Moreover, case-control studies which are common in genomic studies are more problematic for epigenetic marks since sampling cases after disease onset makes it impossible to determine whether epigenetic changes preceded or resulted from the disease. Hence cohort studies or nested case-control studies within cohorts are particularly valuable. Our aim was to examine whether methylation of the repetitive elements *Alu* and LINE-1 was associated with measures of lung function, COPD status, and longitudinal change in lung function in a

1
2
3 cohort of men, the Normative Aging Study. Preliminary results from these analyses were previously
4 reported in abstract form.²³
5
6
7
8
9

10 **METHODS**

11 **Population:**

12
13
14
15
16 Study participants were from the Veterans Administration Normative Aging Study, an ongoing
17 longitudinal study of aging established in 1963.²⁴ This is a cohort of 2,280 healthy male volunteers from
18 the greater Boston, MA, area who were 21–80 years of age at entry and who enrolled after an initial
19 health screening determined that they were free of known chronic medical conditions. Participants were
20 reevaluated every 3–5 years using detailed on-site physical examinations and questionnaires. The study
21 was approved by the Institutional Review Boards of all participating institutions. All participants gave
22 written informed consent.
23
24
25
26
27
28
29

30
31 Prior to 1999, 706 subjects had died and others were either lost to follow-up, being followed by
32 questionnaire only, or had no blood samples left for analyses (n=792). Seven hundred and eighty two
33 subjects had blood samples that were available for methylation analysis resulting in 704 subjects with
34 unique IDs and methylation data as previously described.^{25 26} For this study, individuals evaluated at least
35 once between March 1999 and June 2007 with methylation data and concomitant spirometry were
36 included. During the study period, this included 663 total subjects, 194 of whom reported for blood draw
37 two times, for a total of 857 samples collected. For the analysis of lung function decline, a second
38 spirometric measurement was available on 301 subjects who had had an initial blood draw for
39 methylation measurement.
40
41
42
43
44
45
46
47
48
49

50 **Measures:**

51
52 Spirometry was performed as previously described²⁷ and was repeated up to a maximum of 8
53 spirograms, so that at least 3 acceptable spirograms were obtained, at least 2 of which were reproducible
54 with FEV₁ and FVC measurements within 5% of each spirogram; the best of these 2 values was selected
55
56
57
58
59
60

1
2
3 from a given encounter. Acceptability of spirograms was judged according to ATS standards.^{28 29} All
4 spirometric values are pre-bronchodilator. Percent predicted values for FEV₁ and FVC were calculated
5 using equations by Crapo *et al.*³⁰ COPD was defined as GOLD stage II or higher (FEV₁/FVC<70% and
6 FEV₁<80% predicted).³¹ Techniques for assessing DNA methylation were previously described in
7 detail.^{32 33} Briefly, we performed DNA methylation assessment of *Alu* and LINE-1 repetitive elements on
8 bisulfite-treated blood leukocyte DNA using highly quantitative polymerase chain reaction (PCR)–
9 pyrosequencing technology. The degree of methylation was expressed as the percentage of methylated
10 cytosines over the sum of methylated and unmethylated cytosines. Each marker was tested in triplicate,
11 and their average was used in the statistical analysis.
12
13
14
15
16
17
18
19
20
21
22

23 **Statistical Analysis**

24
25
26 Analyses for cross-sectional associations were performed using repeated measures with
27 adjustment for the correlation between measurements in a given individual using mixed effects models
28 (PROC MIXED) for continuous outcomes (FEV₁, FVC, FEV₁/FVC) and generalized estimating equations
29 (PROC GENMOD) for binary outcomes (COPD). Covariates in multivariable models were chosen for their
30 clinical relevance and strong bivariate associations ($p \leq .05$) with lung function or change in effect estimate
31 criterion of >10% after addition to the model and included age, height, race, pack-years of cigarette
32 smoking, smoking status (dichotomized as current vs. ex and never smokers) and body mass index
33 (BMI). We also considered variables previously associated with methylation of repetitive elements³⁴ such
34 as folate intake, alcohol intake, total white blood cell count and both percent neutrophils and percent
35 lymphocytes. With the exception of percent lymphocytes, which was included in models with LINE-1 only,
36 these covariates were not included in final models because they were not associated with *Alu* or LINE-1
37 methylation and did not meet the change in estimate criteria. Because Figure 2 depicts bivariate
38 relationships, percent predicted values were used for both FEV₁ and FVC to show an adjusted value;
39 actual values for FEV₁ and FVC were utilized in multivariable models. To examine associations between
40 methylation of *Alu* and LINE-1 and change in lung function over time, a rate was calculated using the
41 change in lung function between the two time points divided by the amount of time elapsed between the
42 two measurements in years. This value was utilized as an outcome and analyzed using multivariate linear
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 regression models. A total of 301 subjects had a second lung function data point subsequent to the initial
4 methylation value. SAS version 9.1 (SAS Institute, Cary, NC) was used for all analyses.
5
6
7
8
9

10 RESULTS

11
12
13
14 Baseline characteristics of the 663 individuals included in this study as well as of the subset of
15 301 individuals with two lung function measures are shown in **Table 1**. All subjects were male and the
16 majority (640, 97%) of white race. Forty-three subjects (7%) were current smokers and 197 (30%) were
17 never smokers. There was wide variation in lung function values. Of the 107 individuals with COPD, 77
18 (72%) were GOLD stage II, 26 were stage III and 4 were stage IV; overall 20 (20%) of the individuals with
19 COPD were current smokers.
20
21
22
23
24

25
26 The distribution of percentage methylation of both *Alu* and LINE-1 elements among the
27 population and stratified by smoking status is shown in **Figure 1**.
28
29
30

31 Bivariate relationships between *Alu* and LINE-1 methylation with outcomes and covariates
32 considered for inclusion in the multivariable model are shown in **Table 2**. *Alu* methylation was associated
33 or showed a trend towards association positively with FEV₁, BMI and FEV₁/FVC and negatively with age
34 and COPD status. LINE-1 methylation was positively associated with current smoking and negatively with
35 percent lymphocytes. Neither *Alu* nor LINE-1 methylation was associated with FVC, pack-years of
36 smoking or ever smoking status. Folate intake, alcohol intake, total white blood cell count and percent
37 neutrophils were not significantly associated with *Alu* or LINE-1 methylation in bivariate analyses. There
38 was no significant relationship between methylation of *Alu* and LINE-1 to each other (p=.23).
39
40
41
42
43
44
45
46
47

48 In multivariate models that included age, height, race, pack-years of smoking, smoking status,
49 and BMI, *Alu* methylation was positively associated with FEV₁, and showed a trend towards association
50 with FVC and FEV₁/FVC. Because of recent data suggesting that current smoking status may have
51 differential effects on methylation^{35 36} and because this may relate to disease outcome or risk, we
52 investigated whether our results would change if current smokers were excluded from the analyses.
53
54
55
56
57 Higher *Alu* methylation was still associated with lower odds of COPD (OR 0.80 [0.64, 0.99] p=.046). In
58
59
60

1
2
3 analyses of lung function measures, results were in the same direction but were no longer significant
4
5 except for FEV₁/FVC (FEV₁ p=0.17, FVC p=0.7, FEV₁/FVC p=.029). There were no significant
6
7 associations between LINE-1 methylation and any of the cross-sectional outcomes (**Table 3**). **Figure 2**
8
9 depicts the bivariate associations of *Alu* methylation with FEV₁ % predicted, FVC % predicted and
10
11 FEV₁/FVC.

12
13 We also analyzed whether methylation of *Alu* and LINE-1 were associated with rate of change in
14
15 lung function in a subset of participants who had two consecutive lung function measures (N=301). The
16
17 mean number of years elapsed between measurements was 4.03 (SD 1.23). Models were adjusted for
18
19 baseline FEV₁, FVC or FEV₁/FVC (respectively for the given outcome) as well as age, pack-years of
20
21 smoking, BMI, height, race, percent lymphocytes and smoking status. Relative hypomethylation in LINE-1
22
23 but not *Alu* was associated with faster rate of decline in FEV₁ and FVC (p<.005). Neither measure was
24
25 associated with rate of change of FEV₁/FVC. (**Table 4**) Including both *Alu* and LINE-1 methylation in the
26
27 models did not change the results (data not shown). Because of prior associations between methylation
28
29 of repetitive elements and cardiovascular disease¹⁵⁻¹⁷, we repeated both cross-sectional and longitudinal
30
31 analyses including variables for cardiovascular disease (myocardial infarction, stroke, angina,
32
33 hypertension, ischemic heart disease) and diabetes and found no difference in the results (data not
34
35 shown). Analyses were also repeated in whites only to determine whether results might be due to
36
37 population stratification and results did not change (data not shown). Analyses excluding current smokers
38
39 remained significant (data not shown).

40 41 42 43 **DISCUSSION**

44
45
46 We examined associations between methylation levels of the repetitive elements *Alu* and LINE-1
47
48 in a cohort of older men in relation to lung function and COPD status. In cross-sectional analyses, we
49
50 found that *Alu* hypomethylation was associated with lower FEV₁ with a trend towards association with
51
52 lower FVC and FEV₁/FVC. LINE-1 hypomethylation was associated with more rapid lung function decline
53
54 (FEV₁ and FVC).

1
2
3 Prior studies have found associations between methylation of repetitive transposable elements
4 such as *Alu* and LINE-1 and several diseases including multiple cancers,⁷ cardiovascular disease¹⁵⁻¹⁷ and
5 neurologic disease¹⁸ as well as with markers of inflammation.¹⁹ To our knowledge this is the first study to
6 examine associations between methylation of *Alu* and LINE-1 transposable elements and measures of
7 lung function.
8
9

10
11
12 Previous work has shown that in normal subjects, *Alu* hypomethylation is associated with
13 increased age^{8,37}, greater alcohol use and gender (lower in males).³⁴ In this same cohort (NAS),
14 hypomethylation has been associated with higher incidence of cancer in general and lung cancer
15 specifically (LINE-1 methylation), as well as higher mortality from cancer (*Alu* and LINE-1 methylation).³⁸
16 A variety of environmental exposures such as lead³⁹ traffic particles³³ organic pollutants,⁴⁰ metals, air
17 pollutants and endocrine disrupting agents⁴¹ may all affect global methylation levels, specifically some
18 that may relate to lung function such as various air pollutants.
19
20
21

22
23 Hypomethylation of transposable elements may or may not be causally linked to lower lung
24 function and faster rates of lung function decline. Lower methylation of *Alu* and LINE-1 may increase their
25 activity as retrotransposable sequences, leading to greater genomic instability and more mutations.¹³
26 Furthermore, oxidative damage caused by environmental exposures may cause hypomethylation.⁴² This
27 may lead to alteration of gene expression through a variety of mechanisms including disrupting
28 transcription factor binding sites or reading frames, altering regulatory sequences, altering methylation
29 patterns of gene promoters, or introducing new transcription factor binding sites.⁴³⁻⁴⁵ *Alu* elements
30 specifically are preferentially found in gene-rich regions.⁴⁶ Black carbon and increased PM_{2.5} exposure³³
31 as well as PM₁₀ exposure⁴¹ have been found to be inversely associated with LINE-1 methylation and both
32 *Alu* and LINE-1 methylation, respectively which may impact lung function or lung function decline.⁴⁷ LINE-
33 1 hypomethylation may also increase transcription of genes that have LINE-1 in regulatory regions. It is
34 possible that other specific environmental or dietary exposures previously not known to be associated
35 with lung function may be mediated through epigenetic changes such as *Alu* or LINE-1 hypomethylation.
36 Alternatively, this may be a marker of a specific exposure but not causally linked to lower lung function.
37 Lastly, because *Alu* methylation decreases with increasing age, as does lung function, our findings may
38 represent some other measure of 'aging' or exposures resulting in similar processes beyond just
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 chronological age.⁸ As our understanding of epigenetic processes and the exposures that affect these
4
5 processes increases, the implications of our findings will become clearer.
6

7
8 These data must be interpreted in the context of the study design. Our study was limited to older
9
10 men the majority of whom were white, and our findings may or may not be generalizable to other
11
12 populations. It is difficult to know how to interpret methylation of retrotransposons, as opposed to gene-
13
14 specific methylation, in relation to specific outcomes such as lung function and lung function decline.
15
16 Future studies in this and other cohorts should include gene-specific methylation analyses similar to Qiu
17
18 *et al*²² to elucidate mechanisms by which methylation changes may relate to these outcomes. We did not
19
20 control for a variety of environmental exposures that may be associated with both lung function and
21
22 methylation. However, alteration in methylation patterns may be the pathway through which these
23
24 changes are mediated and thus including these exposures in multivariate models would be overadjusting.
25
26 Methylation levels vary in different tissue types and it is possible that assessments of methylation in
27
28 white blood cells may not reflect alterations seen in lung tissue. However, systemic processes involving
29
30 white blood cells, such as inflammation, may play a role in the pathophysiology of lung function decline⁴⁸
31
32 and may nonetheless be markers of specific exposures (such as cigarette smoking) that exert a systemic
33
34 effect.

35
36 In summary, we found that relative hypomethylation of *Alu* was associated with lower lung
37
38 function measures, and that LINE-1 hypomethylation was associated with more rapid lung function
39
40 decline. Future studies on both gene-specific methylation as well as exposures related to methylation of
41
42 retrotransposons will improve our understanding of the relationship between epigenetic changes and lung
43
44 function, potentially informing new diagnostic and therapeutic approaches to lung function decline and
45
46 diseases such as COPD.
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 1: Baseline characteristics of 663 individuals from the Normative Aging Study and subset of 301 individuals who had more than one lung function measurement for analysis of lung function decline

	Full data set		301 subset	
	Mean (SD) or N (%)	Range	Mean (SD) or N (%)	Range
Age	72.7 (6.7)	(55.3-100.9)	71.5 (6.4)	(55.3-91.0)
BMI	28.5 (4.2)	(19.4-52.3)	28.7 (4.1)	(20.3-52.3)
Pack-years*	30.6 (24.8)	(0.1-145.5)	28.6 (23.1)	(0.10-120.8)
Current smokers	43 (7%)		23 (8%)	
Ever smokers	466 (70%)		216 (70%)	
Folate intake [†] (mcg/day)	570 (333)	(0.23-2235.17)	617 (383)	(0.23-2001.75)
Alcohol intake (gm/day)	12.0 (17.8)	(0-217.8)	10.7 (13.8)	(0-73.5)
WBC (x10 ³ /mm ³)	6.7 (1.8)	(2.7-23.8)	6.6 (2.3)	(3.2-36.6)
% lymphocytes	25.6 (8.0)	(5-88)	25.0 (8.3)	(7-85)
% neutrophils	62.1 (8.7)	(5-85)	62.8 (8.8)	(5-83)
Cardiovascular Disease [‡]	115 (17%)		49 (16%)	
Hypertension	280 (42%)		143 (47%)	
Diabetes	75 (11%)		33 (11%)	
FEV ₁	2.70 (.64)	(.85-4.69)	2.76 (0.62)	(1.29-4.69)
FEV ₁ %pred	81 (17)	(28-125)	81.8 (15.5)	(39.7-122.6)
FVC	3.56 (0.72)	(1.63-6.32)	3.64 (0.71)	(1.63-6.32)
FVC%pred	82 (14)	(43-124)	82.6 (13.1)	(43.8-123.8)
FEV ₁ /FVC	75 (8)	(36-94)	75.6 (7.0)	(51.6-94.4)
COPD	107 (16%)		45 (15%)	
Alu	26.4 (1.1)	(22.8-32.4)	26.4 (1.10)	(22.8-32.3)
LINE-1	76.8 (1.8)	(70.1-84.6)	77.0 (1.8)	(70.1-81.6)

*pack-years in current or ex-smokers only

[†]calculated based on supplement intake and fortified foods from food frequency questionnaire

[‡] angina, stroke, myocardial infarction, ischemic heart disease

Table 2: Bivariate associations between *Alu*, LINE-1 methylation and other covariates

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
Age	-0.3	0.07	-0.2	0.1
BMI	0.106	0.059	0.054	0.17
Current smoking	0.35	0.14	0.697	0.0002
% Lymphocytes	0.08	0.73	-0.31	0.04
FEV ₁	0.024	0.06	-0.006	0.53
FVC	0.023	0.22	-0.004	0.73
FEV ₁ /FVC	0.31	0.046	-0.05	0.67
COPD	OR .87 [.73, 1.03]	0.1	1.02 [.92, 1.13]	0.76

Table 3: Multivariate models for lung function and both *Alu* and LINE-1 methylation*

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
FEV₁	0.028	0.017	-0.015	0.08
FVC	0.027	0.06	-0.017	0.11
FEV₁/FVC	0.3	0.057	-0.092	0.44
COPD	0.85 [0.71, 1.03]	0.09	1.01 [.89, 1.15]	0.83

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status. Models with LINE-1 also include % lymphocytes.

Table 4: Multivariate models for rate of change in lung function (in liters/yr) and both *Alu* and LINE-1 methylation*

	<i>Alu</i>		LINE-1	
	β	p val	β	p val
FEV₁ rate	-0.0028	0.49	-0.0069	0.005
FVC rate	-0.00098	0.84	-0.0096	0.0021
ratio rate	-0.00079	0.17	0.00005	0.89

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status, and baseline FEV₁, FVC or FEV₁/FVC respectively depending on outcome. Models with LINE-1 also adjusted for % lymphocytes.

1
2
3 **Figure Legends**
4

5 **Figure 1:** Distribution (median, interquartile range) of percentage a) *Alu* and b) LINE-1 methylation in the
6 overall cohort and stratified by smoking status
7

8 **Figure 2: *Alu* Methylation and Lung Function**

9 Bivariate associations between *Alu* methylation and FEV₁ %predicted, FVC %predicted and FEV₁/FVC
10

11 * For FEV₁/FVC y axis is percent, not percent predicted
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3 **ACKNOWLEDGMENTS:** We would like to thank all of the participants of the Normative Aging Study.
4

5 **COMPETING INTERESTS:** None of the authors have any competing interests to report.
6

7 **FUNDING:** Funded by NIH grants AG027214, ES015172, ES014663, HL007427, HL089438, ES015172-
8 01 and ES000002, and VA Research and Development Service. Dr. DeMeo is supported by a Doris Duke
9 Clinical Scientist Development Award. The Cooperative Studies Program/Epidemiology Research and
10 Information Center of the U.S. Department of Veterans Affairs supported the VA Normative Aging Study,
11 which is a component of the Massachusetts Veterans Epidemiology Research and Information Center,
12 Boston, MA.
13

14 **AUTHOR CONTRIBUTIONS:** N.E.L. designed the study, performed the data analysis, and prepared the
15 manuscript. J.S. contributed to the data analysis and provided critical revision of the manuscript. L.T.
16 contributed to data collection and provided critical revision of the manuscript. V.B. contributed to data
17 collection and provided critical revision of the manuscript. D.S. and P.V. were involved in conception of
18 the study and critical revision of the manuscript. A.Z. contributed to data collection and provided critical
19 revision of the manuscript. J.S. contributed to study design and provided critical revision of the
20 manuscript. A.B. contributed to data collection and provided critical revision of the manuscript. A.A.L.
21 contributed to study design, assisted with the data analysis, and provided critical revision of the
22 manuscript. D.L.D. designed the study, assisted with the data analysis, and provided critical revision of
23 the manuscript.
24
25
26

27 **DATA SHARING STATEMENT:** There is no additional data available.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

1. Hancock DB, Eijgelsheim M, Wilk JB, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet*;42(1):45-52.
2. Hubert HB, Fabsitz RR, Feinleib M, et al. Genetic and environmental influences on pulmonary function in adult twins. *Am Rev Respir Dis* 1982;125(4):409-15.
3. McClearn GE, Svartengren M, Pedersen NL, et al. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J Gerontol* 1994;49(6):264-8.
4. Redline S, Tishler PV, Rosner B, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. *Am J Epidemiol* 1989;129(4):827-36.
5. Soler Artigas M, Loth DW, Wain LV, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet* 2011;43(11):1082-90.
6. Ehrlich M, Gama-Sosa MA, Huang LH, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. *Nucleic Acids Res* 1982;10(8):2709-21.
7. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. *Biochim Biophys Acta* 2007;1775(1):138-62.
8. Bollati V, Schwartz J, Wright R, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. *Mech Ageing Dev* 2009;130(4):234-9.
9. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409(6822):860-921.
10. Deininger PL, Batzer MA. Alu repeats and human disease. *Mol Genet Metab* 1999;67(3):183-93.
11. Yang AS, Estecio MR, Doshi K. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32(3):e38.
12. Weisenberger DJ, Campan M, Long TI, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33(21):6823-36.
13. Gravina S, Vijg J. Epigenetic factors in aging and longevity. *Pflugers Arch* 2010;459(2):247-58.
14. Dean W, Lucifero D, Santos F. DNA methylation in mammalian development and disease. *Birth Defects Res C Embryo Today* 2005;75(2):98-111.
15. Baccarelli A, Wright R, Bollati V, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology* 2010;21(6):819-28.
16. Castro R, Rivera I, Struys EA, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 2003;49(8):1292-6.
17. Kim M, Long TI, Arakawa K, et al. DNA methylation as a biomarker for cardiovascular disease risk. *PLoS One* 2010;5(3):e9692.
18. Bollati V, Galimberti D, Pergoli L, et al. DNA methylation in repetitive elements and Alzheimer disease. *Brain Behav Immun* 2011.
19. Baccarelli A, Tarantini L, Wright RO, et al. Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. *Epigenetics* 2010;5(3).
20. Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. *Autoimmunity* 2010;43(1):7-16.
21. Sood A, Petersen H, Blanchette CM, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. *Am J Respir Crit Care Med* 2010;182(9):1098-104.
22. Qiu W, Baccarelli A, Carey VJ, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. *Am J Respir Crit Care Med* 2012;185(4):373-81.
23. Lange NE, Sordillo JE, Tarantini L, et al. Global DNA Methylation and Lung Function in the Normative Aging Study [abstract]. *Am J Respir Crit Care Med* 2011;183:A5694.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
24. Bell B, Rose C, Damon A. The Normative Aging Study: an interdisciplinary and longitudinal study of health and aging. *Aging and Human Development* 1972;3:5-17.
25. Madrigano J, Baccarelli A, Mittleman MA, et al. Prolonged exposure to particulate pollution, genes associated with glutathione pathways, and DNA methylation in a cohort of older men. *Environ Health Perspect* 2011;119(7):977-82.
26. Wright RO, Schwartz J, Wright RJ, et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. *Environ Health Perspect* 2010;118(6):790-5.
27. Sparrow D, O'Connor G, Colton T, et al. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function. The Normative Aging Study. *Am Rev Respir Dis* 1987;135(6):1255-60.
28. Standardization of spirometry--1987 update. Statement of the American Thoracic Society. *Am Rev Respir Dis* 1987;136(5):1285-98.
29. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152(3):1107-36.
30. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;123(6):659-64.
31. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2010) at <http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989>
32. Bollati V, Baccarelli A, Hou L, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. *Cancer Res* 2007;67(3):876-80.
33. Baccarelli A, Wright RO, Bollati V, et al. Rapid DNA methylation changes after exposure to traffic particles. *Am J Respir Crit Care Med* 2009;179(7):572-8.
34. Zhu ZZ, Hou L, Bollati V, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. *Int J Epidemiol* 2010.
35. Breitling LP, Yang R, Korn B, et al. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am J Hum Genet* 2011;88(4):450-7.
36. Wan ES, Qiu W, Baccarelli A, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. *Hum Mol Genet* 2012;21(13):3073-82.
37. Jintaridith P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. *Physiol Genomics* 2010;41:194-200.
38. Zhu ZZ, Sparrow D, Hou L, et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. *Cancer Causes Control* 2010;22(3):437-47.
39. Pilsner JR, Hu H, Ettinger A, et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 2009;117(9):1466-71.
40. Rusiecki JA, Baccarelli A, Bollati V, et al. Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. *Environ Health Perspect* 2008;116(11):1547-52.
41. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr* 2009;21(2):243-51.
42. Valinluck V, Tsai HH, Rogstad DK, et al. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 2004;32(14):4100-8.

- 1
2
3
4 43. Norris J, Fan D, Aleman C, et al. Identification of a new subclass of Alu DNA repeats which can
5 function as estrogen receptor-dependent transcriptional enhancers. *J Biol Chem*
6 1995;270(39):22777-82.
7
8 44. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional
9 retinoic acid response element. *Proc Natl Acad Sci U S A* 1995;92(18):8229-33.
10
11 45. Asada K, Kotake Y, Asada R, et al. LINE-1 hypomethylation in a choline-deficiency-induced liver
12 cancer in rats: dependence on feeding period. *J Biomed Biotechnol* 2006;2006(1):17142.
13
14 46. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. *Nat Rev Genet* 2002;3(5):370-9.
15
16 47. Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term
17 exposure to traffic-related air pollution: a cohort study. *Am J Respir Crit Care Med*
18 2010;183(4):455-61.
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
48. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. *Chest* 2011;139(1):165-73.

1
2
3
4
5
6
7
8
9 **Alu and LINE-1 Methylation and Lung Function in the Normative Aging Study**

10 **Short Title: Global Methylation and Lung Function**

11 Nancy E. Lange MD MPH,¹⁻³ Joanne Sordillo ScD^{1,3} Letizia Tarantini BS,⁴ Valentina Bollati PhD,⁴ David
12 Sparrow DSc,⁵ Pantel Vokonas MD,⁵ Antonella Zanobetti PhD,⁶ Joel Schwartz PhD,⁶ Andrea Baccarelli
13 MD PhD,^{4,6} Augusto A. Litonjua MD MPH¹⁻³, Dawn L. DeMeo MD MPH¹⁻³

14
15 | ¹Channing [Laboratory Division of Network Medicine](#), ²Division of Pulmonary and Critical Care Medicine,
16 Department of Medicine, Brigham and Women's Hospital, Boston, MA, USA; ³Harvard Medical School,
17 Boston, MA, USA; ⁴Center of Molecular and Genetic Epidemiology, Department of Environmental and
18 Occupational Health, Università degli Studi di Milano and IRCCS Maggiore Policlinico Hospital,
19 Mangiagalli and Regina Elena Foundation, Milan, Italy; ⁵Veterans Administration Boston Healthcare
20 System and Department of Medicine, Boston University School of Medicine, Boston, MA, USA; ⁶
21 Department of Environmental Health, Harvard School of Public Health, Boston, MA, USA.

22 Corresponding author:

23
24 Nancy E. Lange, MD, MPH
25 Channing Laboratory
26 Brigham and Women's Hospital
27 181 Longwood Avenue, room 454
28 Boston, MA 02115, USA
29 Phone: 617-525-0874
30 Fax: 617-525-0958
31 Email: renal@channing.harvard.edu

32 **Key Words:** epigenetics, global methylation, FEV₁, FVC, exposure

33 **Word count:**

34 Abstract: 217
35 Manuscript: 2057
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: To investigate the association between methylation of transposable elements *Alu* and LINE-1 and lung function.

Design: Cohort study

Setting: Outpatient Veterans Administration facilities in greater Boston, MA, USA.

Participants: Subjects from the Veterans Administration Normative Aging Study, a longitudinal study of aging in men, evaluated between 1999 and 2007. The majority (97%) of subjects were white.

Primary and secondary outcome measures: Primary predictor was methylation, assessed using PCR-pyrosequencing after bisulfite treatment. Primary outcome was lung function as assessed by spirometry, performed according to ATS/ERS guidelines at the same visit as the blood draws.

Results: In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking and race, *Alu* hypomethylation was associated with lower FEV₁ ($\beta=28\text{ml}$ per 1% change in *Alu* methylation, $p=.017$), and showed a trend towards association with a lower FVC ($\beta=27\text{ml}$, $p=.06$) and lower FEV₁/FVC ($\beta=0.3\%$, $p=.058$). In multivariable models adjusted for age, height, BMI, pack-years of smoking, current smoking, % lymphocytes, race and baseline lung function, LINE-1 hypomethylation was associated with more rapid decline of FEV₁ ($\beta=6.9\text{ml/yr}$ per 1% change in LINE-1 methylation, $p=.005$) and of FVC ($\beta=9.6\text{ml/yr}$, $p=.002$).

Conclusions: In multiple regression analysis, *Alu* hypomethylation was associated with lower lung function, and LINE-1 hypomethylation was associated with more rapid lung function decline in a cohort of older and primarily white men from North America. Future studies should aim to replicate these findings

1
2
3
4
5
6
7
8
9 and determine if *Alu* or LINE-1 hypomethylation may be due to specific and modifiable environmental
10 exposures.
11

12
13 **Article Summary:**

14
15 **Article Focus:**

16 Association between methylation, an epigenetic marker, and lung function
17

18 **Key Message(s):**

19 ~~Hypomethylation~~ Relative hypomethylation of transposable elements is associated with lower
20 lung function and more rapid lung function decline in a cohort of elderlyolder North American primarily
21 white men.
22
23
24

25 **Strengths and Limitations:**

26 First study to evaluate methylation of transposable elements in relation to lung function.
27

28 Difficult to interpret implications of methylation patterns in transposable elements.
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

INTRODUCTION

Lung function has both environmental and genetic determinants.¹⁻⁵⁺⁴ Epigenetic changes/variation, which may influence gene expression patterns without changing DNA sequence, may mediate the effects of environmental exposures on disease outcomes. DNA methylation, one type of epigenetic change, is the reversible addition of a methyl group to cytosine nucleotides. Methylation changes may or may not persist over time in the human genome, as epigenetic marks are highly plastic.

A large portion of methylation sites within the genome are found in repeat sequences and transposable elements, such as *Alu* and LINE-1 (long interspersed nuclear element) which are among the most common and best characterized repetitive elements.⁶⁻⁸⁵⁻⁷ *Alu* is the most abundant of the SINEs (short-interspersed nuclear elements) with over one million copies per genome.⁹⁸ *Alu* elements compose approximately 11% of the mass of human genome and contain 30% of its methylation sites.^{7,106-9} LINE-1 elements are present at over half a million copies.^{9,118-40} Methylation of repetitive elements such as *Alu* and LINE-1 has been shown to correlate with total genomic methylation content.^{11,12+0-11} Hypomethylation in transposable elements is associated with higher genomic instability and alterations or deregulation of gene expression.^{13,14+2-13}

Prior studies have found associations between methylation of *Alu* or LINE-1 elements and various diseases including multiple cancers,⁷⁶ cardiovascular disease,¹⁵⁻¹⁷⁺⁴⁻⁴⁶ and neurologic disease,¹⁸⁺⁷ as well as with markers of inflammation,¹⁹⁺⁸ and the inflammatory response.²⁰⁺⁹ Studies on gene-specific methylation and non-neoplastic lung disease have found associations between GATA4, CDKN2A (p16) and lung function and an interaction with wood smoke exposure.²¹⁺²⁰ as well as multiple genes in association with COPD presence and severity.²² To our knowledge no prior study has investigated associations between methylation of transposable elements and non-neoplastic lung disease. Moreover, case-control studies such as which are common in genomic studies are more problematic for epigenetic marks since sampling cases after disease onset makes it impossible to determine whether epigenetic changes preceded or resulted from the disease. Hence cohort studies or nested case-control studies within cohorts are particularly valuable. Our aim was to examine whether methylation of the repetitive elements *Alu* and LINE-1 was associated with measures of lung function, COPD status, and longitudinal

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Formatted: Superscript

1
2
3
4
5
6
7
8
9 change in lung function in a cohort of men, the Normative Aging Study. Preliminary results from these
10 analyses were previously reported in abstract form,^{23,24}

Field Code Changed

14 METHODS

18 Population:

19 Study participants were from the Veterans Administration Normative Aging Study, an ongoing
20 longitudinal study of aging established in 1963.^{24,25} This is a cohort of 2,280 healthy male volunteers from
21 the greater Boston, MA, area who were 21–80 years of age at entry and who enrolled after an initial
22 health screening determined that they were free of known chronic medical conditions. Participants were
23 reevaluated every 3–5 years using detailed on-site physical examinations and questionnaires. The study
24 was approved by the Institutional Review Boards of all participating institutions. All participants gave
25 written informed consent.

26
27
28
29
30
31 Prior to 1999, 706 subjects had died and others were either lost to follow-up, being followed by
32 questionnaire only, or had no blood samples left for analyses (n=792). Seven hundred and eighty two
33 subjects had blood samples that were available for methylation analysis resulting in 704 subjects with
34 unique IDs and methylation data as previously described.^{25,26} For this study, individuals evaluated at least
35 once between January–March 1999 and June 2007 with a blood sample drawn-methylation data and
36 concomitant spirometry were included. During the study period, this included 663 total subjects, 194 of
37 whom reported for examination-blood draw two times, for a total of 857 samples collected. For the
38 analysis of lung function decline, a second spirometric measurement was available on 301 subjects who
39 had had an initial blood draw for methylation measurement.

Formatted: Superscript

46 Measures:

47
48 Spirometry was performed according to ATS/ERS guidelines.²⁹ Spirometry was performed as
49 previously described,²⁷ and was repeated up to a maximum of 8 spirometry, so that at least 3 acceptable
50 spirometry were obtained, at least 2 of which were reproducible with FEV₁ and FVC measurements

Formatted: Superscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

within 5% of each spirogram; the best of these 2 values was selected from a given encounter.

Acceptability of spiograms was judged according to ATS standards.^{28 29} All spirometric values are pre-

Formatted: Superscript

bronchodilator. Percent predicted values for FEV₁ and FVC were calculated using equations by Crapo et

al.^{30 24} COPD was defined as GOLD stage II or higher (FEV₁/FVC < 70% and FEV₁ < 80% predicted).^{31 25}

Field Code Changed

Techniques for assessing DNA methylation were previously described in detail.^{32 33 26 27} Briefly, we

Field Code Changed

performed DNA methylation assessment of *Alu* and LINE-1 repetitive elements on bisulfite-treated blood

leukocyte DNA using highly quantitative polymerase chain reaction (PCR)-pyrosequencing technology.

The degree of methylation was expressed as the percentage of methylated cytosines over the sum of methylated and unmethylated cytosines. Each marker was tested in triplicate, and their average was used in the statistical analysis.

Statistical Analysis

Analyses for cross-sectional associations were performed using repeated measures with adjustment for the correlation between measurements in a given individual using mixed effects models (PROC MIXED) for continuous outcomes (FEV₁, FVC, FEV₁/FVC) and generalized estimating equations (PROC GENMOD) for binary outcomes (COPD). Covariates in multivariable models were chosen for their clinical relevance and strong bivariate associations ($p \leq .05$) with lung function or change in effect estimate criterion of >10% after addition to the model and included age, height, race, pack-years of cigarette smoking, smoking status (dichotomized as current vs. ex and never smokers) and body mass index (BMI). We also considered variables previously associated with methylation of repetitive elements.^{34 28} such as folate intake, alcohol intake, total white blood cell count and both percent neutrophils and percent lymphocytes. With the exception of percent lymphocytes, which was included in models with LINE-1 only, these covariates were not included in final models because they were not associated with *Alu* or LINE-1 methylation and did not meet the change in estimate criteria. Because Figure 2 depicts bivariate relationships, percent predicted values were used for both FEV₁ and FVC to show an adjusted value; actual values for FEV₁ and FVC were utilized in multivariable models. To examine associations between methylation of *Alu* and LINE-1 and change in lung function over time, a rate was calculated using the change in lung function between the two time points divided by the amount of time elapsed between the

Field Code Changed

1
2
3
4
5
6
7
8
9 two measurements in years. This value was utilized as an outcome and analyzed using multivariate linear
10 regression models. A total of 301 subjects had a second lung function data point subsequent to the initial
11 methylation value. SAS version 9.1 (SAS Institute, Cary, NC) was used for all analyses.
12
13

14 15 16 RESULTS

17
18 Baseline characteristics of the 663 individuals included in this study as well as of the subset of
19 301 individuals with two lung function measures are shown in **Table 1**. All subjects were male and the
20 majority (640, 97%) of white race. Few-Forty-three subjects (7%) were current smokers and 197 (30%)
21 were never smokers. There was wide variation in lung function values. Of the 107 individuals with COPD,
22 77 (72%) were GOLD stage II, 26 were stage III and 4 were stage IV; overall 20 (20%) of the individuals
23 with COPD were current smokers.
24
25
26
27

28
29 The distribution of percentage methylation of both *Alu* and LINE-1 elements among the
30 population and stratified by smoking status is shown in **Figure 1**.
31

32
33 Bivariate relationships between *Alu* and LINE-1 methylation with outcomes and covariates
34 considered for inclusion in the multivariable model are shown in **Table 2**. *Alu* methylation was associated
35 or showed a trend towards association positively with FEV₁, BMI and FEV₁/FVC and negatively with age
36 and COPD status. LINE-1 methylation was positively associated with current smoking and negatively
37 with percent lymphocytes. Neither *Alu* nor LINE-1 methylation was associated with FVC, pack-years of
38 smoking or ever smoking status. Folate intake, alcohol intake, total white blood cell count and percent
39 neutrophils were not significantly associated with *Alu* or LINE-1 methylation in bivariate analyses. There
40 was no significant relationship between methylation of *Alu* and LINE-1 to each other (p=.23).
41
42
43
44
45

46
47 In multivariate models that included age, height, race, pack-years of smoking, smoking status,
48 and BMI, *Alu* methylation was positively associated with FEV₁, FEV₁/FVC and showed a trend towards
49 association with FVC and FEV₁/FVC. Because of recent data suggesting that current smoking status may
50 have differential effects on methylation^{35 36} and because this may relate to disease outcome or risk, we
51 investigated whether our results would change if current smokers were excluded from the analyses.
52
53
54

Field Code Changed

Formatted: Superscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Higher *Alu* methylation was still associated with lower odds of COPD (OR 0.80 [0.64, 0.99] p=.046). In analyses of lung function measures, results were in the same direction but were no longer significant except for FEV₁/FVC (FEV₁ p=0.17, FVC p=0.7, FEV₁/FVC p=.029).

When analyzed excluding current smokers, there was a negative association between *Alu* and COPD (higher *Alu* with lower odds of COPD) that was statistically significant (OR 0.80 [0.64, 0.99] p=.046).

There were no significant associations between LINE-1 methylation and any of the cross-sectional outcomes. (Table 3). Figure 2 depicts the bivariate associations of *Alu* methylation with FEV₁ % predicted, FVC % predicted and FEV₁/FVC.

We also analyzed whether methylation of *Alu* and LINE-1 were associated with rate of change in lung function in a subset of participants who had two consecutive lung function measures (N=301). The mean number of years elapsed between measurements was 4.03 (SD 1.23). Models were adjusted for baseline FEV₁, FVC or FEV₁/FVC (respectively for the given outcome) as well as age, pack-years of smoking, BMI, height, race, percent lymphocytes and smoking status. Relative hypomethylation in LINE-1 but not *Alu* was associated negatively with rate of change with faster rate of decline in FEV₁ and FVC (p<.005). Neither measure was associated with rate of change of FEV₁/FVC. (Table 4) Including both *Alu* and LINE-1 methylation in the models did not change the results (data not shown). Because of prior associations between methylation of repetitive elements and cardiovascular disease¹⁵⁻¹⁷, we repeated both cross-sectional and longitudinal analyses including variables for cardiovascular disease (myocardial infarction, stroke, angina, hypertension, ischemic heart disease) and diabetes and found no difference in the results (data not shown). Analyses were also repeated in whites only to determine whether results might be due to population stratification and results did not change (data not shown). Analyses excluding current smokers remained significant (data not shown).

DISCUSSION

We examined associations between methylation levels of the repetitive elements *Alu* and LINE-1 in a cohort of elderly men in relation to lung function and COPD status. In cross-sectional analyses, we found that *Alu* hypomethylation was associated with lower FEV₁ with a trend towards association with

Formatted: Subscript

Formatted: Subscript

Formatted: Superscript

Field Code Changed

lower FVC and FEV₁/FVC. LINE-1 hypomethylation was associated with more rapid lung function decline (FEV₁ and FVC).

Prior studies have found associations between methylation of repetitive transposable elements such as *Alu* and LINE-1 and several diseases including multiple cancers,⁷⁶ cardiovascular disease,^{15-17,14-16} and neurologic disease,^{18,17} as well as with markers of inflammation.^{19,18} To our knowledge this is the first study to examine associations between methylation of *Alu* and LINE-1 transposable elements and measures of lung function.

Previous work has shown that in normal subjects, *Alu* hypomethylation is associated with increased age,^{8,378-34} greater alcohol use and gender (lower in males),^{34,28} In this same cohort (NAS), hypomethylation has been associated with higher incidence of cancer in general and lung cancer specifically (LINE-1 [methylation](#)), as well as higher mortality from cancer (*Alu* and LINE-1 [methylation](#)).^{38,35} A variety of environmental exposures such as lead,^{39,36} traffic particles,^{33,27} organic pollutants,^{40,37} metals, air pollutants and endocrine disrupting agents,^{41,38} may all affect global methylation levels, specifically some that may relate to lung function such as various air pollutants.

Hypomethylation of transposable elements may or may not be causally linked to lower lung function and faster rates of lung function decline. Lower methylation of *Alu* and LINE-1 may increase their activity as retrotransposable sequences, leading to greater genomic instability and more mutations.^{13,42} Furthermore, oxidative damage caused by environmental exposures may cause hypomethylation.^{42,39} This may lead to alteration of gene expression through a variety of mechanisms including disrupting transcription factor binding sites or reading frames, altering regulatory sequences, altering methylation patterns of gene promoters, or introducing new transcription factor binding sites.^{43-45,40-42} *Alu* elements specifically are preferentially found in gene-rich regions.^{46,43} Black carbon and increased PM_{2.5} exposure,^{33,27} as well as PM₁₀ exposure,^{41,38} have been found to be inversely associated with LINE-1 [methylation](#) and both *Alu* and LINE-1 methylation, respectively which may impact lung function or lung function decline.^{47,44} LINE-1 hypomethylation may also increase transcription of genes that have LINE-1 in regulatory regions. It is possible that other specific environmental or dietary exposures previously not known to be associated with lung function may be mediated through epigenetic changes such as *Alu* or LINE-1 hypomethylation. Alternatively, this may be a marker of a specific exposure but not causally

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

Field Code Changed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

linked to lower lung function. Lastly, because *Alu* methylation decreases with increasing age, as does lung function, our findings may represent some other measure of 'aging' or exposures resulting in similar processes beyond just chronological age.⁸⁷ As our understanding of epigenetic processes and the exposures that affect these processes increases, the implications of our findings will become clearer.

Field Code Changed

These data must be interpreted in the context of the study design. Our study was limited to elderly men the majority of whom were white, and our findings may or may not be generalizable to other populations. It is difficult to know how to interpret methylation of retrotransposons, as opposed to gene-specific methylation, in relation to specific outcomes such as lung function and lung function decline. Future studies [in this and other cohorts](#) should include gene-specific methylation analyses [similar to Qiu et al.²²](#) to elucidate mechanisms by which methylation changes may relate to these outcomes. We did not control for a variety of environmental exposures that may be associated with both lung function and methylation. However, alteration in methylation patterns may be the pathway through which these changes are mediated and thus including these exposures in multivariate models would be overadjusting. Methylation levels vary in different tissue types and it is possible that assessments of methylation in white blood cells may not reflect alterations seen in lung tissue. However, systemic processes involving white blood cells, such as inflammation, may play a role in the pathophysiology of lung function decline^{48,46} and may nonetheless be markers of specific exposures (such as cigarette smoking) that exert a systemic effect.

Formatted: Font: Italic

Formatted: Superscript

Field Code Changed

Field Code Changed

In summary, we found that relative hypomethylation of *Alu* was associated with lower lung function measures, and that LINE-1 hypomethylation was associated with more rapid lung function decline. Future studies on both gene-specific methylation as well as exposures related to methylation of retrotransposons will improve our understanding of the relationship between epigenetic changes and lung function, potentially informing new diagnostic and therapeutic approaches to lung function decline [and diseases such as COPD](#).

Table 1: Baseline characteristics of 663 individuals from the Normative Aging Study and subset of 301 individuals who had more than one lung function measurement for analysis of lung function decline

	Mean (SD) or N (%)	Range
Age	72.7 (6.7)	(55.3-100.9)
BMI	28.5 (4.2)	(19.4-52.3)
Pack-years*	30.6 (24.8)	(0.1-145.5)
Current smokers	43 (7%)	-
Ever-smokers	466 (70%)	-
FEV₁	2.70 (.64)	(.85-4.69)
FEV₁%pred	81 (17)	(28-125)
FVC	3.56 (0.72)	(1.63-6.32)
FVC%pred	82 (14)	(43-124)
FEV₁/FVC	75 (8)	(36-94)
COPD	107 (16%)	-
Alu	26.4 (1.1)	(22.8-32.4)
LINE-1	76.8 (1.8)	(70.1-84.6)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

	Full data set		301 subset	
	Mean (SD) or N (%)	Range	Mean (SD) or N (%)	Range
Age	72.7 (6.7)	(55.3-100.9)	71.5 (6.4)	(55.3-91.0)
BMI	28.5 (4.2)	(19.4-52.3)	28.7 (4.1)	(20.3-52.3)
Pack-years*	30.6 (24.8)	(0.1-145.5)	28.6 (23.1)	(0.10-120.8)
Current smokers	43 (7%)		23 (8%)	
Ever smokers	466 (70%)		216 (70%)	
Folate intake [†] (mcg/day)	570 (333)	(0.23-2235.17)	617 (383)	(0.23-2001.75)
Alcohol intake (gm/day)	12.0 (17.8)	(0-217.8)	10.7 (13.8)	(0-73.5)
WBC (x10 ³ /mm ³)	6.7 (1.8)	(2.7-23.8)	6.6 (2.3)	(3.2-36.6)
% lymphocytes	25.6 (8.0)	(5-88)	25.0 (8.3)	(7-85)
% neutrophils	62.1 (8.7)	(5-85)	62.8 (8.8)	(5-83)
Cardiovascular Disease [‡]	115 (17%)		49 (16%)	
Hypertension	280 (42%)		143 (47%)	
Diabetes	75 (11%)		33 (11%)	
FEV ₁	2.70 (.64)	(.85-4.69)	2.76 (0.62)	(1.29-4.69)
FEV ₁ %pred	81 (17)	(28-125)	81.8 (15.5)	(39.7-122.6)
FVC	3.56 (0.72)	(1.63-6.32)	3.64 (0.71)	(1.63-6.32)
FVC%pred	82 (14)	(43-124)	82.6 (13.1)	(43.8-123.8)
FEV ₁ /FVC	75 (8)	(36-94)	75.6 (7.0)	(51.6-94.4)
COPD	107 (16%)		45 (15%)	
Alu	26.4 (1.1)	(22.8-32.4)	26.4 (1.10)	(22.8-32.3)
LINE-1	76.8 (1.8)	(70.1-84.6)	77.0 (1.8)	(70.1-81.6)

*pack-years in current or ex-smokers only

[†]calculated based on supplement intake and fortified foods from food frequency questionnaire

[‡]angina, stroke, myocardial infarction, ischemic heart disease

Table 2: Bivariate associations between *Alu*, LINE-1 [methylation](#) and other covariates

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
Age	-0.3	0.07	-0.2	0.1
BMI	0.106	0.059	0.054	0.17
Current smoking	0.35	0.14	0.697	0.0002
% Lymphocytes	0.08	0.73	-0.31	0.04
FEV ₁	0.024	0.06	-0.006	0.53
FEV ₁ /FVC	0.31	0.046	-0.05	0.67
COPD	OR .87 [.73, 1.03]	0.1	1.02 [.92, 1.13]	0.76

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
Age	-0.3	0.07	-0.2	0.1
BMI	0.106	0.059	0.054	0.17
Current smoking	0.35	0.14	0.697	0.0002
% Lymphocytes	0.08	0.73	-0.31	0.04
FEV ₁	0.024	0.06	-0.006	0.53
FVC	0.023	0.22	-0.004	0.73
FEV ₁ /FVC	0.31	0.046	-0.05	0.67
COPD	OR .87 [.73, 1.03]	0.1	1.02 [.92, 1.13]	0.76

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60**Table 3:** Multivariate models for lung function and both *Alu* and LINE-1 methylation*

	<i>Alu</i>		LINE-1	
	β	p value	β	p value
FEV ₁	0.028	0.017	-0.015	0.08
FVC	0.027	0.06	-0.017	0.11
FEV ₁ /FVC	0.3	0.057	-0.092	0.44
COPD	0.85 [0.71, 1.03]	0.09	1.01 [.89, 1.15]	0.83

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status. Models with LINE-1 also include % lymphocytes.

Table 4: Multivariate models for rate of change in lung function (in liters/yr) and both *Alu* and LINE-1 methylation*

	FEV ₁ rate		FVC rate		ratio rate	
	β	p val	β	p val	β	p val
<i>Alu</i>	-0.0028	0.49	-0.00098	0.84	-0.00079	0.17
LINE-1	-0.0069	0.005	-0.0096	0.0021	0.00005	0.89

	<i>Alu</i>		LINE-1	
	β	p val	β	p val
FEV ₁ rate	-0.0028	0.49	-0.0069	0.005
FVC rate	-0.00098	0.84	-0.0096	0.0021
ratio rate	-0.00079	0.17	0.00005	0.89

*adjusted for age, height, race, BMI, pack-years of smoking, smoking status, and baseline FEV₁, FVC or FEV₁/FVC respectively depending on outcome. Models with LINE-1 also adjusted for % lymphocytes.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure Legends

Figure 1: Distribution (median, interquartile range) of percentage a) *Alu* and b) LINE-1 methylation in the overall cohort and stratified by smoking status

Figure 2: *Alu* Methylation and Lung Function
Bivariate associations between *Alu* and FEV₁%predicted, FVC%predicted and FEV₁/FVC

* For FEV₁/FVC y axis is percent, not percent predicted

For peer review only

1
2
3
4
5
6
7
8
9 **ACKNOWLEDGMENTS:** We would like to thank all of the participants of the Normative Aging Study.

10 **COMPETING INTERESTS:** None of the authors have any competing interests to report.

11
12 **FUNDING:** Funded by NIH grants AG027214, ES015172, ES014663, HL007427, HL089438, ES015172-
13 01 and ES000002, and VA Research and Development Service. Dr. DeMeo is supported by a Doris Duke
14 Clinical Scientist Development Award. The Cooperative Studies Program/Epidemiology Research and
15 Information Center of the U.S. Department of Veterans Affairs supported the VA Normative Aging Study,
16 which is a component of the Massachusetts Veterans Epidemiology Research and Information Center,
17 Boston, MA.

18 **AUTHOR CONTRIBUTIONS:** N.E.L. designed the study, performed the data analysis, and prepared the
19 manuscript. J.S. contributed to the data analysis and provided critical revision of the manuscript. L.T.
20 contributed to data collection and provided critical revision of the manuscript. V.B. contributed to data
21 collection and provided critical revision of the manuscript. D.S. and P.V. were involved in conception of
22 the study and critical revision of the manuscript. A.Z. contributed to data collection and provided critical
23 revision of the manuscript. J.S. contributed to study design and provided critical revision of the
24 manuscript. A.B. contributed to data collection and provided critical revision of the manuscript. A.A.L.
25 contributed to study design, assisted with the data analysis, and provided critical revision of the
26 manuscript. D.L.D. designed the study, assisted with the data analysis, and provided critical revision of
27 the manuscript.
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References:

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
1. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marciano KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet*;42(1):45-52. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 2. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. *Am Rev Respir Dis* 1982;125(4):409-15. Formatted: Font: Calibri, 11 pt, Italic
 3. McClern GE, Svartengren M, Pedersen NL, Heller DA, Plomin R. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J Gerontol* 1994;49(6):264-8. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 4. Redline S, Tishler PV, Rosner B, Lewitter F, Vandenberg M, Weiss ST, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. *Am J Epidemiol* 1989;129(4):827-36. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 5. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet* 2011;43(11):1082-90. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 6. Ehrlich M, Gama-Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. *Nucleic Acids Res* 1982;10(8):2709-21. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 7. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. *Biochim Biophys Acta* 2007;1775(1):138-62. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 8. Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. *Mech Ageing Dev* 2009;130(4):234-9. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 9. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409(6822):860-921. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 10. Deininger PL, Batzer MA. Alu repeats and human disease. *Mol Genet Metab* 1999;67(3):183-93. Formatted: Font: Calibri, 11 pt, Italic
 11. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32(3):e38. Formatted: Font: Calibri, 11 pt
 12. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33(21):6823-36. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 13. Gravina S, Vijg J. Epigenetic factors in aging and longevity. *Pflugers Arch* 2010;459(2):247-58. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 14. Dean W, Lucifero D, Santos F. DNA methylation in mammalian development and disease. *Birth Defects Res C Embryo Today* 2005;75(2):98-111. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 15. Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology* 2010;21(6):819-28. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 16. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 2003;49(8):1292-6. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 17. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. *PLoS One* 2010;5(3):e9692. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 18. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA methylation in repetitive elements and Alzheimer disease. *Brain Behav Immun* 2011. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 19. Baccarelli A, Tarantini L, Wright RO, Bollati V, Litonjua AA, Zanobetti A, et al. Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. *Epigenetics* 2010;5(3). Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
 20. Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. *Autoimmunity* 2010;43(1):7-16. Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
Formatted: Font: Calibri, 11 pt
Formatted: Font: Calibri, 11 pt, Italic
Formatted: Font: Calibri, 11 pt

21. Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. *Am J Respir Crit Care Med* 2010;182(9):1098-104. **Formatted:** Font: Calibri, 11 pt, Italic
22. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. *Am J Respir Crit Care Med* 2012;185(4):373-81. **Formatted:** Font: Calibri, 11 pt, Italic
23. Lange NE, Sordillo JE, Tarantini L, Bollati V, Sparrow D, Vokonas P, et al. Global DNA Methylation and Lung Function in the Normative Aging Study [abstract]. *Am J Respir Crit Care Med* 2011;183:A5694. **Formatted:** Font: Calibri, 11 pt, Italic
24. Bell B, Rose C, Damon A. The Normative Aging Study: an interdisciplinary and longitudinal study of health and aging. *Aging and Human Development* 1972;3:5-17. **Formatted:** Font: Calibri, 11 pt, Italic
25. Madrigano J, Baccarelli A, Mittleman MA, Wright RO, Sparrow D, Vokonas PS, et al. Prolonged exposure to particulate pollution, genes associated with glutathione pathways, and DNA methylation in a cohort of older men. *Environ Health Perspect* 2011;119(7):977-82. **Formatted:** Font: Calibri, 11 pt
26. Wright RO, Schwartz J, Wright RJ, Bollati V, Tarantini L, Park SK, et al. Biomarkers of lead exposure and DNA methylation within retrotransposons. *Environ Health Perspect* 2010;118(6):790-5. **Formatted:** Font: Calibri, 11 pt, Italic
27. Sparrow D, O'Connor G, Colton T, Barry CL, Weiss ST. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function. The Normative Aging Study. *Am Rev Respir Dis* 1987;135(6):1255-60. **Formatted:** Font: Calibri, 11 pt
28. Standardization of spirometry—1987 update. Statement of the American Thoracic Society. *Am Rev Respir Dis* 1987;136(5):1285-98. **Formatted:** Font: Calibri, 11 pt, Italic
29. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152(3):1107-36. **Formatted:** Font: Calibri, 11 pt, Italic
30. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;123(6):659-64. **Formatted:** Font: Calibri, 11 pt
31. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2010) at <http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989>. **Formatted:** Hyperlink, Font: (Default) Calibri, 11 pt
32. Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. *Cancer Res* 2007;67(3):876-80. **Formatted:** Font: Calibri, 11 pt, Italic
33. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH, et al. Rapid DNA methylation changes after exposure to traffic particles. *Am J Respir Crit Care Med* 2009;179(7):572-8. **Formatted:** Font: Calibri, 11 pt
34. Zhu ZZ, Hou L, Bollati V, Tarantini L, Marinelli B, Cantone L, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. *Int J Epidemiol* 2010. **Formatted:** Font: Calibri, 11 pt, Italic
35. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am J Hum Genet* 2011;88(4):450-7. **Formatted:** Font: Calibri, 11 pt, Italic
36. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. *Hum Mol Genet* 2012;21(13):3073-82. **Formatted:** Font: Calibri, 11 pt, Italic
37. Jantaridh P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. *Physiol Genomics* 2010;41:194-200. **Formatted:** Font: Calibri, 11 pt, Italic
38. Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, Litonjua AA, et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. *Cancer Causes Control* 2010;22(3):437-47. **Formatted:** Font: Calibri, 11 pt, Italic
39. Pilsner JR, Hu H, Ettinger A, Sanchez BN, Wright RO, Cantonwine D, et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 2009;117(9):1466-71. **Formatted:** Font: Calibri, 11 pt, Italic

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

40. Rusiecki JA, Baccarelli A, Bollati V, Tarantini L, Moore LE, Bonfeld-Jorgensen EC. Global DNA hypomethylation is associated with high serum-persistent organic pollutants in Greenlandic Inuit. *Environ Health Perspect* 2008;116(11):1547-52.
41. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr* 2009;21(2):243-51.
42. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 2004;32(14):4100-8.
43. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, et al. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. *J Biol Chem* 1995;270(39):22777-82.
44. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. *Proc Natl Acad Sci U S A* 1995;92(18):8229-33.
45. Asada K, Kotake Y, Asada R, Saunders D, Broyles RH, Towner RA, et al. LINE-1 hypomethylation in a choline-deficiency-induced liver cancer in rats: dependence on feeding period. *J Biomed Biotechnol* 2006;2006(1):17142.
46. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. *Nat Rev Genet* 2002;3(5):370-9.
47. Andersen ZJ, Hvidberg M, Jensen SS, Ketzler M, Loft S, Sorensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. *Am J Respir Crit Care Med* 2010;183(4):455-61.
48. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. *Chest* 2011;139(1):165-73.
1. Hancock DB, Eijgelsheim M, Wilk JB, Gharib SA, Loehr LR, Marcicante KD, et al. Meta-analyses of genome-wide association studies identify multiple loci associated with pulmonary function. *Nat Genet* 42(1):45-52.
2. Hubert HB, Fabsitz RR, Feinleib M, Gwinn C. Genetic and environmental influences on pulmonary function in adult twins. *Am Rev Respir Dis* 1982;125(4):409-15.
3. McClearn GE, Svartengren M, Pedersen NL, Heller DA, Plomin R. Genetic and environmental influences on pulmonary function in aging Swedish twins. *J Gerontol* 1994;49(6):264-8.
4. Redline S, Tishler PV, Rosner B, Lewitter FI, Vandenburg M, Weiss ST, et al. Genotypic and phenotypic similarities in pulmonary function among family members of adult monozygotic and dizygotic twins. *Am J Epidemiol* 1989;129(4):827-36.
5. Soler Artigas M, Loth DW, Wain LV, Gharib SA, Obeidat M, Tang W, et al. Genome-wide association and large-scale follow up identifies 16 new loci influencing lung function. *Nat Genet* 2011;43(11):1082-90.
6. Ehrlich M, Gama Sosa MA, Huang LH, Midgett RM, Kuo KC, McCune RA, et al. Amount and distribution of 5-methylcytosine in human DNA from different types of tissues of cells. *Nucleic Acids Res* 1982;10(8):2709-21.
7. Wilson AS, Power BE, Molloy PL. DNA hypomethylation and human diseases. *Biochim Biophys Acta* 2007;1775(1):138-62.
8. Bollati V, Schwartz J, Wright R, Litonjua A, Tarantini L, Suh H, et al. Decline in genomic DNA methylation through aging in a cohort of elderly subjects. *Mech Ageing Dev* 2009;130(4):234-9.
9. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. *Nature* 2001;409(6822):860-921.
10. Deininger PL, Batzer MA. Alu repeats and human disease. *Mol Genet Metab* 1999;67(3):183-93.
11. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite-PCR of repetitive DNA elements. *Nucleic Acids Res* 2004;32(3):e38.

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Font: Calibri, 11 pt, Italic

Formatted: Font: Calibri, 11 pt

Formatted: Indent: Left: 0", First line: 0"


12. Weisenberger DJ, Campan M, Long TI, Kim M, Woods C, Fiala E, et al. Analysis of repetitive element DNA methylation by MethyLight. *Nucleic Acids Res* 2005;33(21):6823-36.
13. Gravina S, Vijg J. Epigenetic factors in aging and longevity. *Pflugers Arch* 2010;459(2):247-58.
14. Dean W, Lucifero D, Santos F. DNA methylation in mammalian development and disease. *Birth Defects Res C Embryo Today* 2005;75(2):98-111.
15. Baccarelli A, Wright R, Bollati V, Litonjua A, Zanobetti A, Tarantini L, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. *Epidemiology* 2010;21(6):819-28.
16. Castro R, Rivera I, Struys EA, Jansen EE, Ravasco P, Camilo ME, et al. Increased homocysteine and S-adenosylhomocysteine concentrations and DNA hypomethylation in vascular disease. *Clin Chem* 2003;49(8):1292-6.
17. Kim M, Long TI, Arakawa K, Wang R, Yu MC, Laird PW. DNA methylation as a biomarker for cardiovascular disease risk. *PLoS One* 2010;5(3):e9692.
18. Bollati V, Galimberti D, Pergoli L, Dalla Valle E, Barretta F, Cortini F, et al. DNA methylation in repetitive elements and Alzheimer disease. *Brain Behav Immun* 2011.
19. Baccarelli A, Tarantini L, Wright RO, Bollati V, Litonjua AA, Zanobetti A, et al. Repetitive element DNA methylation and circulating endothelial and inflammation markers in the VA normative aging study. *Epigenetics* 2010;5(3).
20. Crow MK. Long interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease. *Autoimmunity* 2010;43(1):7-16.
21. Sood A, Petersen H, Blanchette CM, Meek P, Picchi MA, Belinsky SA, et al. Wood smoke exposure and gene promoter methylation are associated with increased risk for COPD in smokers. *Am J Respir Crit Care Med* 2010;182(9):1098-104.
22. Qiu W, Baccarelli A, Carey VJ, Boutaoui N, Bacherman H, Klanderman B, et al. Variable DNA methylation is associated with chronic obstructive pulmonary disease and lung function. *Am J Respir Crit Care Med* 2012;185(4):373-81.
23. Lange NE, Sordillo JE, Tarantini L, Bollati V, Sparrow D, Vokonas P, et al. Global DNA Methylation and Lung Function in the Normative Aging Study [abstract]. *Am J Respir Crit Care Med* 2011;183:A5694.
24. Bell B, Rose C, Damon A. The Normative Aging Study: an interdisciplinary and longitudinal study of health and aging. *Aging and Human Development* 1972;3:5-17.
25. Sparrow D, O'Connor G, Colton T, Barry CL, Weiss ST. The relationship of nonspecific bronchial responsiveness to the occurrence of respiratory symptoms and decreased levels of pulmonary function. The Normative Aging Study. *Am Rev Respir Dis* 1987;135(6):1255-60.
26. Standardization of spirometry—1987 update. Statement of the American Thoracic Society. *Am Rev Respir Dis* 1987;136(5):1285-98.
27. Standardization of Spirometry, 1994 Update. American Thoracic Society. *Am J Respir Crit Care Med* 1995;152(3):1107-36.
28. Crapo RO, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. *Am Rev Respir Dis* 1981;123(6):659-64.
29. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. (Updated 2010) at <http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989>
30. Bollati V, Baccarelli A, Hou L, Bonzini M, Fustinoni S, Cavallo D, et al. Changes in DNA methylation patterns in subjects exposed to low dose benzene. *Cancer Res* 2007;67(3):876-80.
31. Baccarelli A, Wright RO, Bollati V, Tarantini L, Litonjua AA, Suh HH, et al. Rapid DNA methylation changes after exposure to traffic particles. *Am J Respir Crit Care Med* 2009;179(7):572-8.

Formatted: Indent: Left: 0", Hanging: 0.5"

32. Zhu ZZ, Hou L, Bollati V, Tarantini L, Marinelli B, Cantone L, et al. Predictors of global methylation levels in blood DNA of healthy subjects: a combined analysis. *Int J Epidemiol* 2010.
33. Breitling LP, Yang R, Korn B, Burwinkel B, Brenner H. Tobacco-smoking-related differential DNA methylation: 27K discovery and replication. *Am J Hum Genet* 2011;88(4):450-7.
34. Wan ES, Qiu W, Baccarelli A, Carey VJ, Bacherman H, Rennard SI, et al. Cigarette smoking behaviors and time since quitting are associated with differential DNA methylation across the human genome. *Hum Mol Genet* 2012;21(13):3073-82.
35. Jintaridh P, Mutirangura A. Distinctive patterns of age-dependent hypomethylation in interspersed repetitive sequences. *Physiol Genomics* 2010;41:194-200.
36. Zhu ZZ, Sparrow D, Hou L, Tarantini L, Bollati V, Litonjua AA, et al. Repetitive element hypomethylation in blood leukocyte DNA and cancer incidence, prevalence, and mortality in elderly individuals: the Normative Aging Study. *Cancer Causes Control* 2010;22(3):437-47.
37. Pilsner JR, Hu H, Ettinger A, Sanchez BN, Wright RO, Cantonwine D, et al. Influence of prenatal lead exposure on genomic methylation of cord blood DNA. *Environ Health Perspect* 2009;117(9):1466-71.
38. Rusiecki JA, Baccarelli A, Bollati V, Tarantini L, Moore LE, Bonfeld Jorgensen EC. Global DNA hypomethylation is associated with high serum persistent organic pollutants in Greenlandic Inuit. *Environ Health Perspect* 2008;116(11):1547-52.
39. Baccarelli A, Bollati V. Epigenetics and environmental chemicals. *Curr Opin Pediatr* 2009;21(2):243-51.
40. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). *Nucleic Acids Res* 2004;32(14):4100-8.
41. Norris J, Fan D, Aleman C, Marks JR, Futreal PA, Wiseman RW, et al. Identification of a new subclass of Alu DNA repeats which can function as estrogen receptor-dependent transcriptional enhancers. *J Biol Chem* 1995;270(39):22777-82.
42. Vansant G, Reynolds WF. The consensus sequence of a major Alu subfamily contains a functional retinoic acid response element. *Proc Natl Acad Sci U S A* 1995;92(18):8229-33.
43. Asada K, Kotake Y, Asada R, Saunders D, Broyles RH, Towner RA, et al. LINE-1 hypomethylation in a choline deficiency-induced liver cancer in rats: dependence on feeding period. *J Biomed Biotechnol* 2006;2006(1):17142.
44. Batzer MA, Deininger PL. Alu repeats and human genomic diversity. *Nat Rev Genet* 2002;3(5):370-9.
45. Andersen ZJ, Hvidberg M, Jensen SS, Ketzler M, Loft S, Sorensen M, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. *Am J Respir Crit Care Med* 2010;183(4):455-61.
46. Nussbaumer-Ochsner Y, Rabe KF. Systemic manifestations of COPD. *Chest* 2011;139(1):165-73.

Formatted: Indent: Left: 0", Hanging: 0.5"


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (300 x 300 DPI)

View only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60



254x190mm (300 x 300 DPI)

ew only